UPDATE: Mesoblast (MESO) Reports Q1 Loss of $4.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights
November 15, 2018 4:33 PM ESTMELBOURNE, Australia and NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq: MESO) today reported strong financial results and provided operational highlights for the first quarter ended September 30, 2018.
Key financial results for the three months ended September 30, 2018 (first quarter FY2019)
Significant increase in revenues to US$11.6 million in the first quarter FY2019, compared with US$1.2 million in the first quarter FY201866% increase in commercialization revenue from royalty income on sales of TEMCELL®1 HS. Inj. for the quarter, compared with... More